PMID- 29595326
OWN - NLM
STAT- MEDLINE
DCOM- 20190916
LR  - 20221207
IS  - 1473-4877 (Electronic)
IS  - 0300-7995 (Linking)
VI  - 34
IP  - 6
DP  - 2018 Jun
TI  - A real-world analysis of glycemic control among patients with type 2 diabetes 
      treated with canagliflozin versus dapagliflozin.
PG  - 1143-1152
LID - 10.1080/03007995.2018.1458709 [doi]
AB  - OBJECTIVE: This US retrospective cohort study compared the real-world 
      effectiveness of canagliflozin 300 mg versus dapagliflozin 10 mg on HbA1c 
      reduction in patients with type 2 diabetes mellitus (T2DM). METHODS: Patients 
      initiated on canagliflozin 300 mg or dapagliflozin 10 mg were identified from 
      de-identified claims data in the Optum Clinformatics database (1 January 2014-30 
      September 2016). Propensity score matching was used to create balanced cohorts. 
      The primary outcome was the proportion of patients with HbA1c <8.0% (HEDIS 
      target); secondary outcomes included the proportion of patients with HbA1c <7.0% 
      (ADA target) and >9.0% (HEDIS poor control), absolute change in HbA1c, and 
      treatment patterns. RESULTS: At 6 months post-index (intent-to-treat population), 
      a significantly higher proportion of patients in the canagliflozin 300 mg versus 
      dapagliflozin 10 mg cohort achieved HbA1c <8.0% (70.8% vs. 59.1%; OR [95% CI]: 
      1.60 [1.26, 2.04]; p = .0001) and HbA1c <7.0% (36.7% vs. 25.1%; OR [95% CI]: 1.75 
      [1.34, 2.27]; p < .0001). A similar proportion of patients had HbA1c >9.0%. Mean 
      HbA1c reduction was -1.17% with canagliflozin 300 mg and -0.91% with 
      dapagliflozin 10 mg (difference of -0.26%; p = .0049). HbA1c results from a 
      sensitivity analysis in the on-treatment population were consistent with the 
      primary analysis. Patients in the canagliflozin 300 mg versus dapagliflozin 10 mg 
      cohort were less likely to discontinue treatment (OR [95% CI]: 0.75 [0.57, 0.99]; 
      p = .0400) or switch medication (OR [95% CI]: 0.72 [0.54, 0.96]; p = .0229). 
      CONCLUSIONS: In this real-world study, patients with T2DM initiated on 
      canagliflozin 300 mg had better HbA1c goal attainment and larger HbA1c reduction 
      than patients initiated on dapagliflozin 10 mg.
FAU - Blonde, Lawrence
AU  - Blonde L
AD  - a Department of Endocrinology , Ochsner Medical Center , New Orleans , LA , USA.
FAU - Patel, Charmi
AU  - Patel C
AD  - b Janssen Scientific Affairs, LLC , Titusville , NJ , USA.
FAU - Bookhart, Brahim
AU  - Bookhart B
AD  - b Janssen Scientific Affairs, LLC , Titusville , NJ , USA.
FAU - Pfeifer, Michael
AU  - Pfeifer M
AD  - b Janssen Scientific Affairs, LLC , Titusville , NJ , USA.
FAU - Chen, Yen-Wen
AU  - Chen YW
AD  - b Janssen Scientific Affairs, LLC , Titusville , NJ , USA.
FAU - Wu, Bingcao
AU  - Wu B
AD  - b Janssen Scientific Affairs, LLC , Titusville , NJ , USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180420
PL  - England
TA  - Curr Med Res Opin
JT  - Current medical research and opinion
JID - 0351014
RN  - 0 (Benzhydryl Compounds)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0SAC974Z85 (Canagliflozin)
RN  - 1ULL0QJ8UC (dapagliflozin)
SB  - IM
MH  - *Benzhydryl Compounds/administration & dosage/adverse effects
MH  - *Canagliflozin/administration & dosage/adverse effects
MH  - Cohort Studies
MH  - Databases, Factual
MH  - *Diabetes Mellitus, Type 2/blood/drug therapy/epidemiology
MH  - Female
MH  - *Glucosides/administration & dosage/adverse effects
MH  - Glycated Hemoglobin/*analysis
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Practice Patterns, Physicians'
MH  - Propensity Score
MH  - Research Design
MH  - Retrospective Studies
MH  - United States/epidemiology
OTO - NOTNLM
OT  - HbA1c
OT  - Type 2 diabetes mellitus
OT  - canagliflozin
OT  - dapagliflozin
OT  - glycemic control
OT  - real-world
OT  - sodium glucose co-transporter 2
EDAT- 2018/03/30 06:00
MHDA- 2019/09/17 06:00
CRDT- 2018/03/30 06:00
PHST- 2018/03/30 06:00 [pubmed]
PHST- 2019/09/17 06:00 [medline]
PHST- 2018/03/30 06:00 [entrez]
AID - 10.1080/03007995.2018.1458709 [doi]
PST - ppublish
SO  - Curr Med Res Opin. 2018 Jun;34(6):1143-1152. doi: 10.1080/03007995.2018.1458709. 
      Epub 2018 Apr 20.